KLK4 and hereditary angioedema: Double-blind and observational studies have demonstrated the efficacy of plasma-derived and recombinant C1 inhibitors, a kallikrein inhibitor, and a bradykinin B2 receptor inhibitor in treating acute HAE-related angioedema attacks (16–26) (Table 1).